Results 91 to 100 of about 477,715 (269)

CausalCervixNet: convolutional neural networks with causal insight (CICNN) in cervical cancer cell classification—leveraging deep learning models for enhanced diagnostic accuracy

open access: yesBMC Cancer
Cervical cancer is a significant global health issue affecting women worldwide, necessitating prompt detection and effective management. According to the World Health Organization (WHO), approximately 660,000 new cases of cervical cancer and 350,000 ...
Zahra Taghados   +3 more
doaj   +1 more source

Causal Discovery from Changes

open access: yes, 2013
Appears in Proceedings of the Seventeenth Conference on Uncertainty in Artificial Intelligence (UAI2001)
Tian, Jin, Pearl, Judea
openaire   +2 more sources

Transcriptional network analysis of PTEN‐protein‐deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication

open access: yesMolecular Oncology, EarlyView.
Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice   +16 more
wiley   +1 more source

Dagma-DCE: Interpretable, Non-Parametric Differentiable Causal Discovery

open access: yesIEEE Open Journal of Signal Processing
We introduce Dagma-DCE, an interpretable and model-agnostic scheme for differentiable causal discovery. Current non- or over-parametric methods in differentiable causal discovery use opaque proxies of “independence” to justify the inclusion
Daniel Waxman   +2 more
doaj   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

open access: yesMolecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak   +4 more
wiley   +1 more source

Structural gating and effect-aligned lag-resolved temporal causal discovery framework with application to heat–pollution extremes

open access: yesGreen Technologies and Sustainability
This study proposes Structural Gating and Effect-aligned Discovery for Temporal Causal Discovery (SGED-TCD), a novel and general framework for lag-resolved causal discovery in complex multivariate time series. SGED-TCD combines explicit structural gating,
Rui Chen, Jinsong Wu
doaj   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon   +13 more
wiley   +1 more source

Overcoming Confounding Bias in Causal Discovery Using Minimum Redundancy and Maximum Relevancy Constraint

open access: yesIEEE Access
Causal discovery is the process of modeling cause and effect relationships among features. Unlike traditional model-based approaches, that rely on fitting data to the models, methods of causal discovery determine the causal structure from data.
Havisha Nadendla   +2 more
doaj   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

open access: yesMolecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee   +8 more
wiley   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

open access: yesMolecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy